Clovis Oncology (NASDAQ:CLVS) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial.
That data comes from the company’s Phase 3 ATHENA-MONO Trial. This trial saw it testing the effects of Rubraca monotherapy against a placebo in treating women with advanced ovarian cancer. Its use came after treatment with platinum-based chemotherapy.
The big news for Clovis Oncology is that the Phase 3 clinical trial met its primary endpoint. That includes benefits “in both primary efficacy analyses of newly-diagnosed patients with advanced ovarian cancer.”
Read more about CLVS stock here.
The post Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today originally appeared at InvestorPlace.